Blockade of CD82 by a monoclonal antibody potentiates anti‐leukemia effects of AraC in vivo. (3rd July 2015)

• Record Type: Journal Article
• Authors: Nishioka, Chie; Ikezoe, Takayuki; Yokoyama, Akihito
• Is Part Of: Cancer medicine. Volume 4:Number 9(2015:Sep.)
• Page Start: 1426
• Page End: 1431
• Publication Date: 2015-07-03
• Subjects: 616.994005
• DOI: 10.1002/cam4.482
• Languages: English
• ISSNs: 2045-7634

Abstract

<abstract abstract-type="graphical" xml:lang="en" id="cam4482-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The use of anti‐CD82 monoclonal antibody (CD82 mAb) mobilized CD34⁺ leukemia cells from bome marroe into the peripheral blood. The combination of cytarabine and CD82 mAb prolonged survival of immunodeficient mice bearing human AML cells than did treatment with either cytarabin or CD82 mAb alone. <boxed-text content-type="graphic" id="cam4482-blkfxd-0001" position="anchor" orientation="portrait"><graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgj2n0q5hss" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></boxed-text></p> </abstract>